Antitransforming growth factor beta (1D11) for this study was provided by Genzyme Corporation, Framingham, Massachusetts, U.S.A.
Article first published online: 2 JAN 2009
Copyright © 2008 The Triological Society
Volume 118, Issue 3, pages 546–551, March 2008
How to Cite
Simpson, C. B., White, S. and McGuff, H. S. (2008), Anti-Transforming Growth Factor Beta as a Treatment for Laryngotracheal Stenosis in a Canine Model. The Laryngoscope, 118: 546–551. doi: 10.1097/MLG.0b013e31815daf6e
Presented as a poster presentation at the American Bronchoesophagology Session, Combined Otolaryngological Spring Meeting, Phoenix, Arizona, U.S.A., April 30–May 4, 2004.
- Issue published online: 2 JAN 2009
- Article first published online: 2 JAN 2009
- Manuscript Accepted: 10 OCT 2007
- Subglottic stenosis;
- tracheal stenosis;
- growth factors;
- transforming growth factor beta;
- fibrogenic peptide
Objectives/Hypothesis: Laryngotracheal stenosis (LTS) represents a significant treatment dilemma faced by otolaryngologists. Recent topical use of Mitomycin C as an adjunctive treatment has proved helpful but does not completely prevent stenosis. Current literature suggests that transforming growth factor beta (TGFB) plays a significant role in the development of subglottic stenosis. We modified an existing canine model to test antitransforming growth factor beta (anti-TGFB) as a possible treatment for laryngotracheal stenosis.
Study Design: Pilot study in a modified canine model.
Methods: Eight mixed-breed dogs underwent cautery injury to the subglottic region creating subsequent laryngotracheal stenosis. Four dogs were treated with saline injection into the injury site and four dogs were treated with a combination of intravenous (5 mg/kg on day 0 and 5 of the experiment) and local injection of anti-TGFB (50 micrograms).
Results: In the canine model of induced subglottic airway injury, a combination of intralesional and intravenous anti-TGFB results in a reduction in tracheal stenosis (P < .05) and an increase in survival time (P < .03) when compared to the saline control subjects.
Conclusions: Anti-TGFB appears to be a useful adjunct in the treatment of LTS. Further study regarding the optimal dosing, route of administration, and timing of delivery is needed to understand the role of anti-TGFB in the treatment for laryngotracheal stenosis.